id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
CMS-2022-0194-0014,CMS,CMS-2022-0194,Medicare Advantage and Prescription Drug Program: Final Marketing Provisions CFR 422.111(a)(3) and 423.128(a)(3) (CMS-10260),Notice,,2023-04-28T04:00:00Z,2023,4,2023-04-28T04:00:00Z,2023-04-29T03:59:59Z,2023-04-28T13:41:53Z,2023-09053,0,0,090000648599b94a
CMS-2022-0194-0001,CMS,CMS-2022-0194,Medicare Advantage and Prescription Drug Program: Final Marketing Provisions CFR 422.111(a)(3) and 423.128(a)(3) (CMS-10260),Notice,,2022-12-15T05:00:00Z,2022,12,2022-12-15T05:00:00Z,2023-02-14T04:59:59Z,2023-02-16T02:00:47Z,2022-27166,0,0,0900006485538493